= Emerging. More than 5 years before clinical availability. (24.37%, 2023)
= Expected to be clinically available in 1 to 4 years. (39.50%, 2023)
= Clinically available now. (36.13%, 2023)
MSACL 2023 : Jordan

MSACL 2023 Abstract

Self-Classified Topic Area(s): Metabolomics

Podium Presentation in Steinbeck 2 on Thursday at 10:40 (Chair: Daniel Globisch / Emma Guiberson)

Abstract withdrawn by presenter on March 27, 2023
Low Plasma Glutamine is Associated with Poor Outcomes in a Cohort of Acute Heart Failure Patients

Helen Jordan, Sarir Sarmad, Toru Suzuki, Leong Ng
University of Leicester, Leicester, United Kingdom

Helen Jordan, BSc (Presenter)
University of Leicester

Presenter Bio: Hi, my name is Helen and I am in my final few months as a PhD student at the University of Leicester. My PhD thesis is titled "Investigation of novel metabolomic biomarkers of heart failure". I have pursued two different biomarkers in my PhD. One amino acid and one lysophosphatidylcholine. Both of these I have discovered in untargeted work and then progressed onto quantifying them in a large clinical cohort of heart failure patients.
In April, when my thesis is finished, I will be moving across the Atlantic to join the Thomas lab at the University of Minnesota for 6 months. Here I will use proteomics for the first time, as my PhD has been predominantly metabolomics with a little bit of lipidomics.


This abstract has been withdrawn from presentation.

Financial Disclosure

GrantsyesShimadzu UK (supplement my PhD stipend)
Board Memberno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above: